# Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)

> **NCT06640491** · PHASE1,PHASE2 · RECRUITING · sponsor: **The Methodist Hospital Research Institute** · enrollment: 40 (estimated)

## Conditions studied

- Total Knee Arthroplasty

## Interventions

- **DRUG:** IO Administration of Cefazolin
- **DRUG:** IO Administration of Vancomycin
- **DRUG:** IV Administration of Cefazolin
- **DRUG:** IV Administration of Vancomycin

## Key facts

- **NCT ID:** NCT06640491
- **Lead sponsor:** The Methodist Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-15
- **Primary completion:** 2030-12-01
- **Final completion:** 2035-12-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06640491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06640491, "Intraosseous (IO) Cefazolin and Vancomycin in Primary Total Knee Arthroplasty (TKA)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06640491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*